FrancophonIA/ELRC3.0 huggingface dataset:
English: The fifth, smaller study compared the combination with lisinopril and hydrochlorothiazide (another combination used to treat hypertension) in 130 patients with severe hypertension.
Slovenian: V peti, manjši študiji s 130 bolniki s hudo hipertenzijo so kombinacijo primerjali s kombinacijo lizinoprila in hidroklorotiazida (drugo kombinacijo zdravil za zdravljenje zvišanega krvnega tlaka).
English: How does Copalia work?
Slovenian: Kako zdravilo Copalia deluje?
English: What is Copalia used for?
Slovenian: Za kaj se zdravilo Copalia uporablja?
English: Copalia contains two active substances, amlodipine and valsartan.
Slovenian: Zdravilo Copalia vsebuje dve zdravilni učinkovini, amlodipin in valsartan.
English: How has Copalia been studied?
Slovenian: Kako je bilo zdravilo Copalia raziskano?
English: What is Copalia?
Slovenian: Kaj je zdravilo Copalia?
English: How is Copalia used?
Slovenian: Kako se zdravilo Copalia uporablja?
English: Sweden Mundipharma AB Mölndalsvägen 30B Göteborg
Slovenian: Mundipharma AB Mölndalsvägen 30B Göteborg
English: Mundipharma AS Dicks vei 10B, 1366 Lysaker
Slovenian: Norveška Mundipharma AS Dicks vei 10B, 1366
English: Mundipharma Farmaceutica Lda Rua Duque de Palmela, no 23, Lisboa
Slovenian: Portugalska Mundipharma Farmaceutica Lda Rua Duque de Palmela, no 23, Lisboa
English: Annex I List of the names, pharmaceutical form(s), strength(s) of the medicinal product(s), route(s) of administration, marketing authorisation holder(s) in the member states
Slovenian: Priloga I Seznam imen, farmacevtskih oblik, jakosti zdravila, poti uporabe zdravila,
English: Mundipharma Pharmaceuticals B.V.
Slovenian: Nizozemska Mundipharma Pharmaceuticals B.V.
English: Germany Mundipharma GmbH Mundipharma Str. 2, Limburg
Slovenian: Mundipharma GmbH Mundipharma Str. 2, Limburg
English: Luxembourg Mundipharma Comm. VA Blarenberglaan 3C
Slovenian: Luksemburg Mundipharma Comm. VA Blarenberglaan 3C
English: Luxembourg Mundipharma Comm. VA Blarenberglaan 3C,
Slovenian: Luksemburg Mundipharma Comm. VA Blarenberglaan 3C,
English: Belgium Mundipharma Comm. VA Blarenberglaan 3C,
Slovenian: Mundipharma Comm. VA Blarenberglaan 3C, Mechelen
English: Germany Mundipharma GmbH Mundipharma Str. 2
Slovenian: Mundipharma GmbH Mundipharma Str. 2 Limburg
English: Further information on Rizmoic can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/rizmoic
Slovenian: Nadaljnje informacije o zdravilu Rizmoic so na voljo na spletni strani agencije: ema.europa.eu/medicines/human/EPAR/rizmoic
English: The recommended dose is one tablet once daily, which the patient can take with or without a laxative.
Slovenian: Priporočeni odmerek je ena tableta enkrat na dan, ki jo bolnik lahko jemlje sočasno z odvajalnim sredstvom ali brez njega.
English: The European Medicines Agency therefore decided that Rizmoic's benefits are greater than its risks and it can be authorised for use in the EU.
Slovenian: Evropska agencija za zdravila je zato zaključila, da so koristi zdravila Rizmoic večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
English: What measures are being taken to ensure the safe and effective use of Rizmoic?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Rizmoic?
English: Rizmoic is available as 200 microgram tablets.
Slovenian: Zdravilo Rizmoic je na voljo v obliki 200-mikrogramskih tablet.
English: As for all medicines, data on the use of Rizmoic are continuously monitored.
Slovenian: Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Rizmoic stalno spremljajo.
English: Other information about Rizmoic
Slovenian: Druge informacije o zdravilu Rizmoic
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Rizmoic have been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Rizmoic upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
English: The majority of side effects in patients with or without cancer were mild to moderate.
Slovenian: Večina neželenih učinkov pri bolnikih z rakom ali brez njega je bila blagih do zmernih.
English: Furthermore, the side effects of Rizmoic, which mainly affected the gut, were mostly mild or moderate.
Slovenian: Poleg tega so bili neželeni učinki zdravila Rizmoic, ki so predvsem prizadeli črevesje, večinoma blagi ali zmerni.
English: Side effects reported with Rizmoic are carefully evaluated and any necessary action taken to protect patients.
Slovenian: Neželeni učinki, o katerih so poročali pri zdravilu Rizmoic, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
English: Why is Rizmoic authorised in the EU?
Slovenian: Zakaj je zdravilo Rizmoic odobreno v EU?
English: Because molecules of naldemedine were designed not be able to enter into the brain, the medicine does not block opioids from working on pain receptors in the brain and therefore does not interfere with pain relief.
Slovenian: Ker so bile molekule naldemedina zasnovane tako, da ne morejo vstopiti v možgane, zdravilo Rizmoic ne preprečuje delovanja opioidov na bolečinske receptorje v možganih in torej ne zavira lajšanja bolečin.
English: An overview of Rizmoic and why it is authorised in the EU
Slovenian: Pregled zdravila Rizmoic in zakaj je odobreno v EU
English: The studies compared Rizmoic with placebo (a dummy treatment) to see if treatment would consistently increase the number of patients who can pass stools and allow them to do so at least 3 times a week during treatment.
Slovenian: V študijah so primerjali zdravilo Rizmoic s placebom (zdravilom brez učinkovine), da bi ugotovili, ali zdravljenje dosledno poveča število bolnikov, ki lahko odvajajo blato, in jim omogoča, da to storijo vsaj trikrat tedensko med zdravljenjem.
English: For more information about using Rizmoic, see the package leaflet or contact your doctor or pharmacist.
Slovenian: Za več informacij glede uporabe zdravila Rizmoic glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
English: In two other studies, involving 307 patients taking opioids for cancer pain, 74% of patients taking Rizmoic for two weeks achieved the desired outcome compared with 36% of patients taking placebo.
Slovenian: V dveh drugih študijah, v katerih je sodelovalo 307 bolnikov, ki so jemali opioidna zdravila za lajšanje bolečin zaradi rakavih obolenj, je 74 % bolnikov, ki so dva tedna jemali zdravilo Rizmoic, doseglo želeni rezultat v primerjavi s 36 % bolnikov, ki so jemali placebo.
English: In patients with cancer, the most common side effects were diarrhoea (seen in more than 1 in 10 people) and abdominal pain (seen in up to 1 in 10 people).
Slovenian: Pri bolnikih z rakom so bili najpogostejši neželeni učinki driska (opaženi pri več kot 1 osebi od 10) in bolečine v trebuhu (opaženi pri največ 1 osebi od 10).
English: Rizmoic must not be used in patients with a blocked or perforated bowel or patients at high risk of bowel blockage.
Slovenian: Zdravilo Rizmoic se ne sme uporabljati pri bolnikih z zaporo ali perforacijo črevesja ali bolnikih z visokim tveganjem za zaporo črevesja.
English: What are the risks associated with Rizmoic?
Slovenian: Kakšna tveganja so povezana z zdravilom Rizmoic?
English: What benefits of Rizmoic have been shown in studies?
Slovenian: Kakšne koristi je zdravilo Rizmoic izkazalo v študijah?
English: What is Rizmoic and what is it used for?
Slovenian: Kaj je zdravilo Rizmoic in za kaj se uporablja?
English: The most common side effects with Rizmoic in patients without cancer (which may affect up to 1 in 10 people) are abdominal pain (belly ache), diarrhoea, nausea and vomiting.
Slovenian: Najpogostejši neželeni učinki zdravila Rizmoic pri bolnikih brez rakavih obolenj (ki se lahko pojavijo pri največ 1 osebi od 10) so bolečine v trebuhu, driska, slabost in bruhanje.
English: In two of the studies, involving 1095 patients taking opioids for chronic (long-term) pain caused by a condition other than cancer, 50% of patients taking Rizmoic for 12 weeks achieved the desired outcome, compared with 34% of patients taking placebo.
Slovenian: V dveh študijah, v katerih je sodelovalo 1 095 bolnikov, ki so jemali opioide za lajšanje kronične (dolgotrajne) bolečine zaradi drugih bolezni, razen rakavih obolenj, je 50 % bolnikov, ki so zdravilo Rizmoic jemali 12 tednov, doseglo želeni rezultat v primerjavi s 34 % bolnikov, ki so jemali placebo.
English: Constipation is the most common side effect of opioid pain medicines and many standard laxatives are not effective in treating the condition.
Slovenian: Najpogostejši neželeni učinek opioidnih protibolečinskih zdravil je zaprtje, številna standardna odvajala pri zdravljenju tega stanja pa niso učinkovita.
English: The patient must stop taking Rizmoic when they are no longer taking an opioid.
Slovenian: Če bolnik ne prejema več opioidnih zdravil, mora prenehati jemati zdravilo Rizmoic.
English: Rizmoic has been shown to improve bowel movement in patients taking opioids pain medicines for long-term pain (including cancer pain).
Slovenian: Zdravilo Rizmoic je dokazano izboljšalo odvajanje blata pri bolnikih, ki jemljejo opioidna protibolečinska zdravila za zdravljenje dolgotrajne bolečine (vključno z bolečinami zaradi rakavih obolenj).
English: Studies have shown that Rizmoic is effective at improving bowel movement in patients who are currently taking laxatives or had taken laxatives in the past.
Slovenian: Študije so pokazale, da je zdravilo Rizmoic učinkovito pri izboljševanju odvajanja blata pri bolnikih, ki trenutno jemljejo odvajala ali so jih jemali v preteklosti.
English: Rizmoic is a medicine for treating constipation caused by opioid pain relief medicines in patients who have previously been treated with a laxative (a medicine that triggers bowel movements).
Slovenian: Rizmoic je zdravilo za zdravljenje zaprtja, ki ga povzročajo opioidna zdravila za lajšanje bolečin, pri bolnikih, ki so pred tem že bili zdravljeni z odvajali (zdravili za spodbujanje odvajanja blata).
English: The active substance in Rizmoic, naldemedine, works by attaching to and blocking receptors in the gut (mu-, delta- and kappa-opioid receptors), through which opioid medicines cause constipation.
Slovenian: Učinkovina v zdravilu Rizmoic, naldemedin, deluje tako, da se veže na receptorje v črevesju (mu, delta in kapa opioidne receptorje) in jih zavira.
English: Rizmoic can only be obtained with a prescription.
Slovenian: Predpisovanje in izdaja zdravila Rizmoic je le na recept.
English: How is Rizmoic used?
Slovenian: Kako se zdravilo Rizmoic uporablja?
English: How does Rizmoic work?
Slovenian: Kako zdravilo Rizmoic deluje?
English: It contains the active substance naldemedine.
Slovenian: Vsebuje učinkovino naldemedin.
English: Packaging Content
Slovenian: Velikost pakiranja
English: To benefit from your medicine you should take it regularly every day at the same time of the day.
Slovenian: Da bi vam zdravilo koristilo, ga morate jemati redno, vsak dan ob istem času.
English: ● amantadine (for the treatment of Parkinson's disease),
Slovenian: • amantadin (za zdravljenje Parkinsonove bolezni),
English: In case of signs and symptoms of general central nervous system (CNS) overstimulation, careful symptomatic clinical treatment should be considered.
Slovenian: Pri znakih in simptomih splošne prekomerne stimulacije centralnega živčnega sistema (CŽS) je treba razmisliti o previdnem simptomatskem kliničnem zdravljenju.
English: The patient received symptomatic treatment and plasmapheresis.
Slovenian: Bolnik je bil deležen simptomatskega zdravljenja in plazmafereze.
English: ● dantrolene, baclofen
Slovenian: • dantrolen, baklofen
English: If you are allergic to peanut or soya, do not take this medicinal product.
Slovenian: Če ste alergični na arašide ali sojo, ne uporabljajte tega zdravila.
English: 2 Isolated cases reported in post-marketing experience.
Slovenian: 2 Posamezni primeri, o katerih so poročali v okviru izkušenj v obdobju trženja.
English: A. MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
Slovenian: A. IZDELOVALCI, ODGOVORNI ZA SPROŠČANJE SERIJ B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE C. DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET Z ZDRAVILOM D. POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO
English: ● Do not take a double dose to make up for a forgotten dose.
Slovenian: • Ne vzemite dvojnega odmerka, če ste pozabili vzeti prejšnji odmerek.
English: Children and adolescents Memantine ratiopharm is not recommended for children and adolescents under the age of 18 years.
Slovenian: Otroci in mladostniki Zdravila Memantin ratiopharm ne priporočajo otrokom in mladostnikom, mlajšim od 18 let.
English: ● cimetidine, ranitidine, procainamide, quinidine, quinine, nicotine
Slovenian: • cimetidin, ranitidin, prokainamid, kinidin, kinin, nikotin
English: Adverse reactions are ranked according to system organ class, using the following convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
Slovenian: Neželeni učinki so razporejeni glede na organske sisteme ob uporabi naslednjega dogovora: zelo pogosti (≥1/10); pogosti (≥1/100 do < 1/10); občasni (≥ 1/1.000 do < 1/100); redki (≥ 1/10.000 do <1/1.000); zelo redki (< 1/10.000), neznana pogostnost (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti).
English: Other Anti-dementia drugs, ATC code: N06DX01.
Slovenian: Druga zdravila za zdravljenje demence, oznaka ATC: N06DX01.
English: Slabinská 30, 03680 Martin Slovakia
Slovenian: Slabinská 30, 03680 Martin Slovaška
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 13 June 2013
Slovenian: Datum prve odobritve: 13. junij 2013 Datum zadnjega podaljšanja:
English: SL-03680 Martin Slovakia
Slovenian: SL-03680 Martin Slovaška
English: Headache Fatigue 1 Hallucinations have mainly been observed in patients with severe Alzheimer's disease.
Slovenian: Pogosti Občasni glavobol utrujenost 1 Halucinacije so bile večinoma opažene pri bolnikih s hudo Alzheimerjevo boleznijo.
English: The 10 mg and 20 mg tablet can be divided into equal doses.
Slovenian: 10 mg in 20 mg tableta se lahko deli na enake odmerke.
English: Pharmacotherapeutic group: Psychoanaleptics.
Slovenian: Farmakoterapevtska skupina: psihoanaleptiki.
English: Very Rare (affects less than 1 user in 10,000): ● Seizures
Slovenian: Zelo redki (pojavijo se pri manj kot 1 bolniku od 10.000 bolnikov): • epileptični napadi
English: Shelf life after first opening: 6 months 6.4 Special precautions for storage Blister packs
Slovenian: Rok uporabe po prvem odprtju: 6 mesecev 6.4 Posebna navodila za shranjevanje Pretisni omoti
English: Take one tablet once a day.
Slovenian: Vzemite eno tableto enkrat dnevno.
English: Relative large overdoses (200 mg and 105 mg/day for 3 days, respectively) have been associated with either only symptoms of tiredness, weakness and/or diarrhoea or no symptoms.
Slovenian: Sorazmerno veliki preveliki odmerki (200 mg dnevno oziroma 105 mg dnevno, tri dni) so bili povezani samo s simptomi utrujenosti, šibkosti in/ali driske ali pa simptomov sploh ni bilo.
English: ● dopaminergic agonists (substances such as L-dopa, bromocriptine)
Slovenian: • dopaminergični agonisti (učinkovine kot L-dopa, bromokriptin)
English: Not known (frequency cannot be estimated from the available data): ● Inflammation of the pancreas, inflammation of the liver (hepatitis) and psychotic reactions
Slovenian: Neznana pogostnost (pogostosti ni mogoče oceniti iz razpoložljivih podatkov): • vnetje trebušne slinavke, vnetje jeter (hepatitis) in psihotične reakcije
English: B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE Medicinal product subject to restricted prescription (see Annex I: Summary of Product Characteristics, section 4.2).
Slovenian: B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE Predpisovanje in izdaja zdravila je le na recept s posebnim režimom (glejte Prilogo I: Povzetek glavnih značilnosti zdravila, poglavje 4.2).
English: From Week 4 on:
Slovenian: Od 4. tedna dalje:
English: The most frequently occurring adverse reactions with a higher incidence in the memantine group than in the placebo group were dizziness (6.3% vs 5.6%, respectively), headache (5.2% vs 3.9%), constipation (4.6% vs 2.6%), somnolence (3.4% vs 2.2%) and hypertension (4.1% vs 2.8%).
Slovenian: Najpogostejši neželeni učinki, ki so se pogosteje pojavili pri skupini bolnikov, ki je jemala memantin, kot pri skupini, ki je prejemala placebo, so bili omotica (6,3 % proti 5,6 %), glavobol (5,2 % proti 3,9 %), zaprtje (4,6 % proti 2,6 %), zaspanost (3,4 % proti 2,2 %) in hipertenzija (4,1 % proti 2,8 %).
English: Your doctor will tell you whether your illness allows you to drive and to use machines safely.
Slovenian: Vpliv na sposobnost upravljanja vozil in strojev Vaš zdravnik vam bo povedal, če zaradi vaše bolezni lahko varno vozite in varno upravljate stroje.
English: - Other active substances such as cimetidine, ranitidine, procainamide, quinidine, quinine and nicotine that use the same renal cationic transport system as amantadine may also possibly interact with memantine leading to a potential risk of increased plasma levels.
Slovenian: - Ostale učinkovine, kot cimetidin, ranitidin, prokainamid, kinidin, kinin in nikotin, ki uporabljajo isti ledvični kationski transportni sistem kot amantadin, prav tako lahko medsebojno reagirajo z memantinom, kar lahko vodi do zvišanih vrednosti v plazmi.
English: Alzheimer's disease has been associated with depression, suicidal ideation and suicide.
Slovenian: Obstaja povezava med Alzheimerjevo boleznijo in depresijo, samomorilnimi mislimi in samomorom.
English: In the most extreme case of overdose, the patient survived the oral intake of a total of 2000 mg memantine with effects on the central nervous system (coma for 10 days, and later diplopia and agitation).
Slovenian: V najhujšem primeru prevelikega odmerka je bolnik preživel peroralni vnos 2000 mg memantina z učinki na centralni živčni sistem (desetdnevna koma, kasneje diplopija in vznemirjenost).
English: The brain contains so-called N-methyl-D-aspartate (NMDA)-receptors that are involved in transmitting nerve signals important in learning and memory.
Slovenian: V možganih se nahajajo tako imenovani receptorji N-metil-D-aspartan (NMDA), ki sodelujejo v prenosu živčnih signalov, ki so pomembni za učenje in spomin.
English: ● oral anticoagulants
Slovenian: • peroralni antikoagulanti
English: If tolerated well after at least 7 days of treatment, the dose could be increased up to 20 mg/day according to standard titration scheme.
Slovenian: Če bolnik zdravljenje dobro prenaša, se lahko odmerek po najmanj 7 dneh zdravljenja zviša do 20 mg dnevno, po standardni titracijski shemi.
English: - In post-marketing experience, isolated cases with international normalized ratio (INR) increases have been reported in patients concomitantly treated with warfarin.
Slovenian: - V okviru izkušenj v obdobju trženja so poročali o posameznih primerih povečanja mednarodno umerjenega razmerja (INR) pri bolnikih, ki so bili sočasno zdravljeni z varfarinom.
English: Hypersensitivity to the active substance, peanut or soya or to any of the excipients listed in section 6.1.
Slovenian: Preobčutljivost na učinkovino, arašide, sojo ali katero koli pomožno snov, navedeno v poglavju 6.1.
English: In volunteers with normal kidney function, total clearance (Cltot) amounts to 170 ml/min/1.73 m2 and part of total renal clearance is achieved by tubular secretion.
Slovenian: Pri prostovoljcih z normalnim delovanjem ledvic je celoten očistek (Cltot) 170 ml/min/1,73 m²; del celotnega ledvičnega očistka je dosežen s pomočjo tubularne sekrecije.
English: ● if you have recently experienced a myocardial infarction (heart attack), or if you are suffering from congestive heart failure or from an uncontrolled hypertension (high blood pressure).
Slovenian: • če ste pred kratkim preboleli srčni infarkt (srčna kap), imate kongestivno srčno odpoved ali neurejeno hipertenzijo (visok krvni tlak).
English: - The mode of action suggests that the effects of L-dopa, dopaminergic agonists, and anticholinergics may be enhanced by concomitant treatment with NMDA-antagonists such as memantine.
Slovenian: - Na podlagi mehanizma delovanja se pričakuje, da se učinki L-dope, dopaminergičnih agonistov in antiholinergikov lahko okrepijo ob sočasnem zdravljenju z antagonisti NMDA kot je memantin.
English: - There may be a possibility of reduced serum level of hydrochlorothiazide (HCT) when memantine is co-administered with HCT or any combination with HCT.
Slovenian: - Obstaja možnost zmanjšane serumske koncentracije hidroklorotiazida (HCT) ob sočasni uporabi memantina in HCT oziroma kakršnikoli kombinacij s HCT.
English: This medicine contains soya lecithin.
Slovenian: To zdravilo vsebuje sojin lecitin.
English: ● amantadine, ketamine, dextromethorphan
Slovenian: • amantadin, ketamin, dekstrometorfan
English: ● ketamine (a substance generally used as an anaesthetic),
Slovenian: • ketamin (učinkovina, ki se običajno uporablja kot anestetik),
English: The recommended treatment dose of 20 mg per day is achieved by a gradual increase of the Memantine ratiopharm dose during the first 3 weeks of treatment.
Slovenian: Priporočeni vzdrževalni odmerek 20 mg na dan, se doseže s postopnim povečevanjem odmerka zdravila Memantin ratiopharm v prvih treh tednih zdravljenja.
English: PHARMACEUTICAL FORM AND CONTENTS Treatment initiation pack
Slovenian: FARMACEVTSKA OBLIKA IN VSEBINA Pakiranje za začetno zdravljenje
English: Do not use this medicine after the expiry date which is stated on the carton and the blister pack after EXP.
Slovenian: Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in na pretisnem omotu poleg oznake EXP. Rok uporabnosti zdravila se izteče na zadnji dan navedenega meseca.
English: Each pack of 28 film-coated tablets for a 4 week treatment schedule contains: 7 x 5 mg and 7 x 10 mg and 7 x 15 mg and 7 x 20 mg film-coated tablets
Slovenian: Eno pakiranje z 28 filmsko obloženimi tabletami za 4-tedenski program zdravljenja vsebuje: 7 x 5 mg in 7 x 10 mg in 7 x 15 mg in 7 x 20 mg filmsko obloženih tablet
English: From the fourth week on, the usual dose is two tablets once a day (1x 20 mg).
Slovenian: Od četrtega tedna naprej je običajni odmerek dve tableti enkrat dnevno (1 x 20 mg).
English: ● hydrochlorothiazide (or any combination with hydrochlorothiazide)
Slovenian: • hidroklorotiazid (ali kombinacije zdravil, ki vsebujejo hidroklorotiazid)
English: ● barbiturates (substances generally used to induce sleep)
Slovenian: • barbiturati (zdravila, ki se na splošno uporabljajo kot uspavala)
English: ● dextromethorphan (generally used to treat cough) and
Slovenian: • dekstrometorfan (običajno se uporablja za zdravljenje kašlja) in
English: Somnolence Confusion Hallucinations1
Slovenian: Neznana pogostnost zaspanost zmedenost halucinacije1 psihotične reakcije2
English: The Memantine ratiopharm treatment initiation pack is only to be used for the beginning of the treatment with Memantine ratiopharm.
Slovenian: Pakiranje za začetno zdravljenje zdravila Memantin ratiopharm se uporablja samo na začetku zdravljenja z zdravilom Memantin ratiopharm.
English: Memantine ratiopharm belongs to a group of medicines called NMDA-receptor antagonists.
Slovenian: Zdravilo Memantin ratiopharm spada v skupino zdravil, ki se imenujejo antagonisti receptorjev NMDA.
English: Memantine ratiopharm is available in packs with 28 (7 +7 +7 + 7) film-coated tablets.
Slovenian: Zdravilo Memantin ratiopharm je na voljo v pakiranjih po 28 (7 + 7 + 7 + 7) filmsko obloženih tablet.
English: Common (affects 1 to 10 users in 100):
Slovenian: Pogosti (pojavijo se pri 1 do 10 bolnikov od 100 bolnikov):